

## In Andrew's Portfolio – Emergent Biosolutions Inc EBS on the NYSE [US]

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing and developing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. Through manufacturing vaccines and antibody therapeutics, these are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent BioSolutions Inc., incorporated in May 5, 1998, is a biopharmaceutical company The Company operates in two divisions: Bio-Defence Division and Bio-Sciences Division.

### Company Facts [web site](#)

Ticker	Market Cap	Sector	Exchange	Currency	Indices
EBS	\$1.97bn	Biotechnology	NYSE	US \$	n/a

### Key Features

- Emergent BioSolutions Inc is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life.
- It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
- The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease.
- Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, chloride).
- 1300 Employees, 13 Global locations, 2016 \$489 2016 Total Revenue. 8 Marketed products involving vaccines for Biological and Chemical threats
- [Presentation Video - BioSolutions](#)
- [Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government](#)
- [Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility](#)
- Successful in gaining new Procurement and Development Contracts and has aligned business structure for Vaccines, Antibody Therapeutics, and Contract Manufacturing.
- Has a 2016-2020 growth strategy in place and ideally placed to become a key player in US concerns on global security issues.
- Emergent Solutions uniquely positioned to offer products and services for the growing global public health threat
- Effective company mission to Prepare, Prevent Protect
- Year on year share performance increase 26%. (2 Jan 2018 \$47.97 Jan 2017 \$38.09)

### Recent News

- [Bio-solutions reported 3<sup>rd</sup> Quarter Results 2017](#)
- Awarded a five-year follow-on contract valued at up to \$171 million by the U.S. Department of Defense (DoD) to supply RSDL<sup>®</sup> (Reactive Skin Decontamination Lotion Kit) for use by all branches of the S. military
- Awarded a contract valued at up to approximately \$25 million by the U.S. Department of State to supply TROBIGARD<sup>™</sup> (Atropine Sulfate [2mg]/Obidoxime Chloride [220mg]) auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning
- [News Release for Bio-Solutions](#)

## Key Statistics

- [Analyst Estimates](#)




## Financial Performance

- [Bio- Solutions Snap shot of Finances for Bio Solutions](#)
- [Financial Statements 2014-2016](#)

## Recent Third Quarter 2017 Results

	9 Mnths(Sept) ended 2016 \$ mil	9 Mnths(Sept) ended 2017 \$ mil	Change %
Total Revenues	337.1	367.1	8.90
Net Income	30.2	48.7	61.3
EBITDA	80.4	100.8	25.4

**TECHNICAL ANALYSIS** – Technical Diagnosis –Emergent Biosolutions share price for 2017 has been on an incline. The 50 Day and 100 Day Moving Averages have remained in a constant trending rising momentum. The 20 Day Moving Average has since the beginning of 2017 been upward rising following the share price with consistency. It would be expected that continued momentum to the upside will be reflected in 50 and 100 day Moving Averages if share price continues to rise in 2018. In December 2017 the share price broke the last high of June 2015 suggesting that a new support level has now been established around \$44. Mid December 2017 saw the price exceed this new support level thereby suggesting that a break out from its previous high had occurred. Confirmation that Emergent has seen growth momentum has been established through the Aroon indicator pattern set up. The cross-over of aroons are very important as this often provides guidance when a change of direction is imminent. This happened in early December and the share price since then has been in positive ascendancy. When the respective Aroons keep within their respective segments of strength, (Aroon UP above 50 and Aroon Down below 50) this implies that the strength of the price move is consistent with continued positive investor sentiment. Since May 2017 for the majority of the time Aroon UP has consistently been in the 50+ positive segment and Aroon Down been in the 50- negative segment. Continuance of this pattern in the future provides myself with confidence that momentum will continue. (Note a 20 period Aroon is being used) Last months candlestick performance has seen gradual bullish upside. 2018 has seen a robust start with the high of 2nd January surpassing recent highs of \$47. The fundamental nature of the company passing holds in favour with the uncertainty posed by global threats and consistent with US policy to prepare, prevent and protect. The company have been awarded several procurement and development contracts including a five-year follow-on contract valued at up to \$171 million by the U.S. Department of Defence (DoD) to supply RSDL<sup>®</sup> (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military. This together with recent confirming technicals incline me to support this share as a worthwhile proposition believing that medium to long time price appreciation to be in evidence for the future. I decided to buy 215 Shares @ \$46.79 on 29 December. A further purchase of 107 shares at @\$51.21 on 19 January and @\$53.60 on 23 March was executed following the continued robustness of the share performance since the original share purchase. **Please note this analysis is not advice but interpretation of potential market moves. Performance is no guide to the future.** First Share Reviewed on 2 Jan 2018 at \$47.97 Current Price 20 May 2018 \$52.00



Visitors are advised to conduct independent research